Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment
- PMID: 32774906
- PMCID: PMC7391108
- DOI: 10.1155/2020/6138132
Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment
Abstract
Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal ganglion cells and their axons. Lowering of intraocular pressure (IOP) is currently the only proven treatment strategy for glaucoma. However, some patients show progressive loss of visual field and quality of life despite controlled IOP which indicates that other factors are implicated in glaucoma. Therefore, approaches that could prevent or decrease the rate of progression and do not rely on IOP lowering have gained much attention. Effective neuroprotection has been reported in animal models of glaucoma, but till now, no neuroprotective agents have been clinically approved. The present update provides an overview of currently available IOP-lowering medications. Moreover, potential new treatment targets for IOP-lowering and neuroprotective therapy are discussed. Finally, future trends in glaucoma therapy are addressed, including sustained drug delivery systems and progress toward personalized medicine.
Copyright © 2020 Barbara Cvenkel and Miriam Kolko.
Conflict of interest statement
The authors declare that there are no conflicts of interest regarding this work.
Similar articles
-
Present and New Treatment Strategies in the Management of Glaucoma.Open Ophthalmol J. 2015 May 15;9:89-100. doi: 10.2174/1874364101509010089. eCollection 2015. Open Ophthalmol J. 2015. PMID: 26069521 Free PMC article.
-
[Aiming for zero blindness].Nippon Ganka Gakkai Zasshi. 2015 Mar;119(3):168-93; discussion 194. Nippon Ganka Gakkai Zasshi. 2015. PMID: 25854109 Review. Japanese.
-
Neuroprotective agents in the management of glaucoma.Eye (Lond). 2018 May;32(5):938-945. doi: 10.1038/s41433-018-0050-2. Epub 2018 Feb 23. Eye (Lond). 2018. PMID: 29472700 Free PMC article. Review.
-
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.Prog Retin Eye Res. 2017 Jan;56:107-147. doi: 10.1016/j.preteyeres.2016.10.001. Epub 2016 Oct 20. Prog Retin Eye Res. 2017. PMID: 27773767 Free PMC article. Review.
-
Upregulation of the endothelin A (ETA) receptor and its association with neurodegeneration in a rodent model of glaucoma.BMC Neurosci. 2017 Mar 1;18(1):27. doi: 10.1186/s12868-017-0346-3. BMC Neurosci. 2017. PMID: 28249604 Free PMC article.
Cited by
-
Assessment of the Effectiveness of Glaucoma Treatment Using MicroPulse Transscleral Cyclophotocoagulation in Patients with Glaucoma Who Have Previously Undergone Vitreoretinal Surgery.Ophthalmol Ther. 2023 Feb;12(1):179-193. doi: 10.1007/s40123-022-00598-5. Epub 2022 Nov 2. Ophthalmol Ther. 2023. PMID: 36324053 Free PMC article.
-
Symptomatic Presbyopia may Develop Earlier in Patients With Glaucoma-A Cross-Sectional Retrospective Cohort Study.Transl Vis Sci Technol. 2024 Apr 2;13(4):21. doi: 10.1167/tvst.13.4.21. Transl Vis Sci Technol. 2024. PMID: 38619925 Free PMC article.
-
Cerebral Modifications in Glaucoma and Macular Degeneration: Analysis of Current Evidence in Literature and Their Implications on Therapeutic Perspectives.Eye Brain. 2021 Jun 17;13:159-173. doi: 10.2147/EB.S307551. eCollection 2021. Eye Brain. 2021. PMID: 34168513 Free PMC article. Review.
-
Rho Kinase (ROCK) Inhibitors in the Treatment of Glaucoma and Glaucoma Surgery: A Systematic Review of Early to Late Phase Clinical Trials.Pharmaceuticals (Basel). 2025 Apr 3;18(4):523. doi: 10.3390/ph18040523. Pharmaceuticals (Basel). 2025. PMID: 40283958 Free PMC article. Review.
-
Nanomedicine in glaucoma treatment; Current challenges and future perspectives.Mater Today Bio. 2024 Sep 4;28:101229. doi: 10.1016/j.mtbio.2024.101229. eCollection 2024 Oct. Mater Today Bio. 2024. PMID: 39296355 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources